Apyx Medical Corporation (APYX)

The past six months have seen several events impacting APYX stock. Apyx Medical reported its second-quarter 2025 financial results, which included the successful initial launch of the AYON Body Contouring System and the initiation of commercial sales of Renuvion in China. A virtual Key Opinion Leader event was announced to discuss the commercial launch of the AYON Body Contouring System. The full U.S. commercial launch of the AYON Body Contouring System was initiated, with demand for pre-orders exceeding expectations. A new 510(k) for AYON was submitted for device label expansion. Apyx Medical was initiated with a "buy" rating by Roth Capital. Preliminary fourth-quarter and full-year 2025 revenue results were announced, indicating significant growth. A sell signal was issued from a pivot top point, leading to a decline in the stock. Apyx Medical's shares advanced 26% in the thirty days leading up to February 3, 2026, and a substantial 210% over the past year.

Demand for Apyx Medical's products and services exhibits seasonality. The third quarter is typically slower than the second and fourth quarters, primarily due to summer vacations. The fourth quarter is generally anticipated to be the strongest for the Advanced Energy segment. The company's guidance for the second half of 2024 implied stronger year-over-year growth, aligning with historical seasonality.

Apyx Medical Corporation is a surgical aesthetics company focused on advanced energy technology, enhancing lives through innovative products in cosmetic surgery and the broader medical technology sector. The company operates within the medical device industry, specifically targeting surgical and interventional procedures. Apyx Medical's major products include its Helium Plasma Platform Technology products, marketed as Renuvion® and J-Plasma®. The company also offers the AYON Body Contouring System™, an FDA-cleared, all-in-one platform. Beyond these, Apyx Medical's product portfolio encompasses electrosurgery generators and accessories, veterinary products, and other medical products. The company also engages in OEM agreements.

Apyx Medical Corporation is headquartered in Clearwater, Florida, USA, and maintains manufacturing facilities in Clearwater, Florida, and Sofia, Bulgaria. Apyx Medical serves doctor's offices, surgery centers, and hospitals, marketing its products directly and through a global network of distributors. Its primary market is the United States, with a strategic expansion into international markets, including North America, Europe, and select other international regions.

Apyx Medical has experienced several positive developments impacting its brand reputation over the past year. Renuvion received the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener." Two peer-reviewed clinical studies evaluating Renuvion's use in body contouring procedures were published. Dolores Catania was appointed as Chief of Confidence for Renuvion's "Renew You" consumer marketing campaign. Renuvion was highlighted at Miami Swim Week. The initial feedback from surgeons regarding the AYON Body Contouring System has been overwhelmingly positive. The company's stock performance reflects positively on its market perception. Analysts have given Apyx Medical a consensus rating of "Moderate Buy." TradeSmith's Health Indicator has placed APYX in the "Green zone" for over nine months.

Apyx Medical Corporation has a significant institutional ownership presence, with 67 institutional owners and shareholders holding a total of 18,339,788 shares. Major institutional holders include Nantahala Capital Management, LLC, Archon Capital Management LLC, Royce & Associates, LP, The Vanguard Group, Inc., and BlackRock, Inc. Top mutual fund holders include Vanguard Index Funds - Vanguard Total Stock Market ETF and The Royce Fund - Royce Small-Cap Opportunity Fund. Overall, mutual funds and ETFs hold 12.86% of shares outstanding, other institutional investors hold 33.71%, and public companies & retail investors hold 53.43%.